‘Universal’ group B Streptococcus vaccine created

	Tweet

Group B Streptococcus - commonly called GBS - is a disease-causing bug that comes in a number of variations, which has made it difficult to produce a useful vaccine. Now, by screening the genome of several subtypes of the bacterium, scientists have come up with a ‘universal’ GBS vaccine.

GBS is the most common cause of life-threatening bacterial infections in newborns. In most cases it is acquired from the mother during the birth process. While various vaccines against GBS are now being tested in clinical trials, they only offer protection against the most common strains in the US, not against subtypes encountered in other parts of the world.

To develop a GBS vaccine that provides broader protection, Dr. Guido Grandi, from Chiron srl in Siena, Italy, and colleagues analyzed the genetic make-up of eight GBS subtypes. From this, they identified and tested 312 GBS surface proteins that might serve as vaccine components.

Four proteins appeared to play a key role in triggering an immune response, the researchers report in the journal Science. Alone, each antigen elicited strong protection in mice against corresponding GBS strains. Combined into one vaccine, the proteins provided strong protection against a wide range of GBS strains.

This approach “provides the basis for the potential development of universal protein-based vaccines against other important and highly variable pathogens, such as Group A Streptococcus and Streptococcus pneumoniae,” the researchers point out.

SOURCE: Science, July 1, 2005.

RELATED STORIES:
Obesity drug helpful for polycystic ovaries   J&J recalls drug after glass found in bottle   Viagra helps climbers deal with high altitudes   Study: Plavix saves lives after big heart attacks   Ortho-McNeil to lower the price of contraceptive pills and patches   FDA approves automated hepatitis C virus assay on ADVIA Centaur Immunoassay system   Existing Drugs Considered to Treat Addiction   Brand-name prescription drug prices rise   FDA Approves Relenza for Prevention of Seasonal Flu   Risks of old, new diet drugs face U.S. scrutiny   Sponge contraceptive returning to market   Mozambique malaria vaccine trials show good result

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]